HPLC determination of bezafibrate in human plasma and its application to pharmacokinetics studies

Journal of Chromatographic Science

Volumn 48, Issue 5, 2010, Pages 362-366

  De Melo, Janine ^a   Hurtado, Felipe Kellermann ^a   Poitevin, Fabia Silveira ^a   Flores, Fernanda Cramer ^a   Zimmermann, Estevan Sonego ^a   Dalmora, Sergio Luiz ^a   Rolim, Clarice Madalena Bueno ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953038424     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/48.5.362     Document Type: Article

References (14)

1. B. Lamarche, J.P. Despres, S. Moorjani, B. Cantin, G.R. Dagenais, and P.J. Lupien. Triglycerides and HDL-cholesterol as risk factors for ischemic hearth diseases: results from the Quebec Cardiovascular Study. Atheroscler. 119: 235-245 (1996).
2. T. Hirano, T. Kazumi, and G. Yoshino. Long-term efficacy of bezafibrate in reduction of small, dense low-density lipoprotein by hypotriglyceridemic action. Curr. Ther. Res. 61: 127-136 (2000).
3. L. Komsta, G. Misztal, E. Majchrzak, and A. Hauzer. Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals. J. Pharm. Biomed. Anal. 41: 408-414 (2006).
4. A. Krebs, B. Starczewska, and E. Leszczynska. Spectrophotometric determination of bezafibrate by ternary complex formation with palladium (II) chloride and eosin. Anal. Lett. 39: 2453-2462 (2006).
5. L. Komsta and G. Misztal. Application of UV-derivative spectra for determination of four antihyperlipidaemic drugs in pharmaceutical formulations. Acta Pol. Pharm. 61: 9-13 (2004).
6. G.Misztal and L. Komsta. Study of the liquid chromatography retention of some fibrate-type antihyperlipidemic drugs on C18 and CN columns: application for quantitation in pharmaceutical formulations. J. AOAC Int. 88: 479-489 (2005).
7. J. Melo, F.K. Hurtado, M.J. Souza, A.W. Prado, and C.M.B. Rolim. Validation of HLPC and UV spectrophotometric methods for the determination of bezafibrate in pharmaceutical formulations. J. Liq. Chromatogr. Relat. Tech. 31: 269-280 (2008).
8. L.D. Masnatta, L.A. Cuniberti, R.H. Rey, and J.P. Werba. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. J. Chromatogr. B 687: 437-442 (1996).
9. D. Castoldi, V. Monzani, and O. Tofanetti. Determination of bezafibrate in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 344: 259-265 (1985).
10. H. Ledermann and B. Kaufman. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slowrelease preparation and the currently available commercial form. J. Int.Med. Res. 9: 516-520 (1981).
11. R. Gandini, R. Assereto, D. Castoldi, E. Cunietti, P. Garanzelli, and W. Monzani. Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man. Pak. J. Pharm. Sci. 7: 149-155 (1987).
12. B. Vens-Cappell, C. Hilgenstock, M. Gellert, K. Kuhle, I. Reifferscheid, P.Winckler, and K.G. Buhrens. Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration. 2. Multiple-dose administration and chronopharmacokinetics. Arzneimittelforschung 43: 346-356 (1993).
13. O. Ali, M.A. Khan, R.Obaid, and S.W. Ahmed. Bioavailability study of tablet bezafibrate 200 mg (Lipocor). Pak. J. Pharm. Sci. 15: 35-34 (2002).
14. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, Center for Drug Evaluation and Research, Rockville, MD, 2001, pp. 1-22.